Efficacy and tolerability of carbamazepine for the treatment of painful diabetic neuropathy in adults: a 12-week, open-label, multicenter study

Figures & data

Table 1 Baseline characteristics of patients

Characteristics	Mean (SD)*
Sex, n (%)
Male	288 (63.7)
Female	164 (36.3)
Age, years	48.1±11.3
FPG, mg/dL	173.6±68.1
Diabetes, years	10.5±6.5
Creatinine, mg/dL	1.65±0.91
ALT, mg/dL	40.5±14.8

Notes: N=452.

* Data are expressed as mean (± SD) unless otherwise specified.

Abbreviations: ALT, alanine aminotransferase; FPG, fasting plasma glucose; SD, standard deviation.

Figure 1 Change in neuropathic pain and quality of life (QoL) from baseline to week 12.

Note: The data represent pain severity, pain interference, and QoL scores at baseline and week 12.

Table 2 Adverse events (AEs) during the study period

AE	n (%)
Drowsiness	4 (0.9)
Headache	3 (0.7)
Mild dizziness	1 (0.2)
Nausea	2 (0.4)